The New Semaglutide Pill Approved in the UK — What You Should Know

What the trial data showed, and how to read the headline figures

The MHRA's approval rested on the OASIS 4 phase-3 trial: 307 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes, treated for 64 weeks alongside lifestyle changes. The average weight loss was around 13.6% on semaglutide versus 2.4% on placebo. Among participants who followed the regimen without interruption, that figure rose to approximately 17%, a result that catches the eye, but it's worth understanding what it measures. The 17% reflects the best-case adherence group, not the typical participant. Both figures are meaningful; neither is the whole picture on its own.

For context, the weekly semaglutide injection at its standard 2.4 mg dose produced roughly 15% average weight loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. If you are researching how a semaglutide pill works and what sets it apart from the injection, the tablet's 13.6% average sits slightly below that, which makes sense given the different absorption challenge oral semaglutide faces. The SNAC absorption enhancer built into each tablet addresses this, but oral bioavailability of semaglutide is inherently lower than subcutaneous delivery. That gap narrows considerably in the adherent-participant group, and it may narrow further as the 25 mg maintenance dose becomes established in clinical practice.

What the trial did not show: long-term cardiovascular outcomes data equivalent to those available for the injection. That evidence base is still maturing. A prescriber assessing your suitability will weigh the available evidence against your individual health picture, which is precisely why clinical review sits at the centre of the process, not the periphery.

How the tablet fits into the semaglutide licensing picture

Semaglutide exists in several licensed forms in the UK, and the distinctions matter. The weekly injection (Wegovy, 0.25 mg up to 2.4 mg or 7.2 mg) is licensed for weight management. Ozempic, also a semaglutide injection, is licensed for type 2 diabetes, not weight loss. Rybelsus tablets (3 mg, 7 mg, 14 mg) are oral semaglutide licensed for type 2 diabetes. The new Wegovy tablet is the only oral semaglutide product currently licensed in the UK for weight management, and its dose steps (1.5 mg, 4 mg, 9 mg, 25 mg) are entirely separate from the Rybelsus strengths. People researching semaglutide pills across the different licensed products sometimes encounter references to a 3 mg or 7 mg semaglutide tablet in a weight-loss context, but those refer to Rybelsus and are being presented incorrectly.

The MHRA licensed the Wegovy tablet for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. If you are already established on the 2.4 mg weekly injection, the approved guidance allows a move directly to the 25 mg tablet, subject to a prescriber's assessment. You can read more about the full range of semaglutide tablet options and how they differ if you want to understand the landscape before a consultation.

The MHRA's approval announcement for the single-dose 7.2 mg pen earlier in 2026 shows how quickly the semaglutide licensing picture is moving, the tablet approval followed just a few months later. That pace is a reason to check current guidance with a prescriber rather than relying on articles written even six months ago.

The practical difference a tablet makes, storage, routine, and the 30-minute rule

The storage point is genuinely useful for many people. The Wegovy injection must be kept refrigerated, which creates complications for travel, shared fridges, or anyone who simply forgets the pen is in the fridge door until it has been sitting at room temperature too long. The tablet lives at room temperature. Drop it in a handbag or coat pocket; no cool bag, no ice pack, no hotel minibar negotiation required.

The trade-off is a strict morning routine. The tablet should be taken first thing on an empty stomach with a small amount of plain water, roughly up to 120 ml. You then wait at least 30 minutes before eating, drinking anything other than water (including coffee), or taking other oral medicines. That half-hour window is not optional; it exists because semaglutide's oral absorption is sensitive to food, drink and competing medicines. For people whose mornings are already structured, this is straightforward. For those who wake up and immediately make a coffee, it requires a small but consistent habit change.

People with questions about how the tablet compares to the injection in practical terms often find the Wegovy tablet overview useful as a starting point, and the explanation of how oral semaglutide is absorbed fills in the science behind the 30-minute rule. Missed doses, timing adjustments and what to do if you vomit shortly after taking a tablet are all covered in the Patient Information Leaflet and should be discussed with your prescriber, this page does not substitute for that guidance.

NHS availability, private access, and what comes next

At launch, the Wegovy tablet is available through private prescription only. The NHS does not commission a medicine until NICE has completed a formal technology appraisal and NHS England has issued commissioning guidance. That process typically takes a year or more after licensing. There is no NICE appraisal underway for the Wegovy tablet at the time of writing (summer 2026), so NHS access is not imminent. Anyone who suggests otherwise is getting ahead of the evidence.

For context on cost, the Wegovy tablet pricing page sets out what private treatment currently involves and what a legitimate price should include, consultation, prescription, delivery and clinical aftercare. A prescription-only medicine that appears without any clinical assessment attached to the order is a red flag, regardless of the price.

The injection pathway continues alongside the tablet; neither replaces the other, and which suits a given person depends on their circumstances, medical history and preferences. If you are considering treatment and want to understand the full picture of weight-loss medicine options currently available, that is a good place to explore before a consultation. Our prescribers at nume carry out a same-day clinical review of every consultation, a named clinician reads your answers, not an automated system. If the tablet is suitable for you, they will confirm it; if another route is more appropriate, they will explain why. Start your free consultation at our treatment page.